Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts

Journal of Gene Medicine

Volumn 3, Issue 4, 2001, Pages 326-337

  Wetzel, K ^a   Menten, P ^b   Opdenakker G ^b   Van Damme, J ^b   Grone H J ^a   Giese, N ^a   Vecchi, A ^c   Sozzani, S ^c   Cornelis, J J ^a   Rommelaere, J ^a   Dinsart, C ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Dendritic cells; Gene therapy; MCP 3 chemokine; Natural killer cell; Parvoviral vector

Indexed keywords

H 1 VIRUS; HELICOBACTER HEILMANNII TYPE 1; MUS MUSCULUS; PARVOVIRUS; PARVOVIRUS H1;

CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 3; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GENETICS; HELA CELL; HUMAN; MOUSE; NUDE MOUSE; PARVOVIRUS; PLASMID; UTERINE CERVIX TUMOR; XENOGRAFT;

ANIMALS; CYTOKINES; FEMALE; HELA CELLS; HUMANS; MICE; MICE, NUDE; MONOCYTE CHEMOATTRACTANT PROTEINS; PARVOVIRUS; PLASMIDS; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 18044399537     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.191     Document Type: Article

References (62)

1. Berns KI. Parvoviridae: the viruses and their replication. In Fields Virology, Fields BN, Knipe DM, Howley PM (eds.). Lipincott-Raven: Philadelphia, 1996; 2173-2197.
2. Siegl G. Variability, adaptability and epidemiology of autonomous parvoviruses. In Handbook of Parvoviruses, Tijssen P (ed.). CRC Press: Boca Raton, 1990; 59-74.
3. Deleu L, Pujol A, Faisst S, et al. Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J Virol 1999; 73: 3877-3885.
4. Jacoby RO, Ball-Goodrich LJ, Besselsen DG, et al. Rodent parvovirus infections. Lab Anim Sci 1996; 46: 370-380.
5. Caillet-Fauquet P, Perros M, Brandenburger A, et al. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989-2995.
6. Rayet B, Lopez-Guerrero JA, Rommelaere J, et al. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998; 72: 8893-8903.
7. Cornelis JJ, Becquart P, Duponchel N, et al. Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 1988; 62: 1679-1686.
8. Salome N, van Hille B, Duponchel N, et al. Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes. Oncogene 1990; 5: 123-130.
9. Faisst S, Guittard D, Benner A, et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer 1998; 75: 584-589.
10. Haag A, Menten P, Van Damme J, et al. High efficient transduction and expression of cytokine genes into human tumor cells by means of autonomous parvovirus vectors: generation of antitumor responses in recipient mice. Hum Gene Ther 2000; 11: 597-609.
11. Russell SJ, Brandenburger A, Flemming CL, et al. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-2828.
12. Dupont F, Tenenbaum L, Guo LP, et al. Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. J Virol 1994; 68: 1397-1406.
13. Kestler J, Neeb B, Struyf S, et al. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999; 10: 1619-1632.
14. Lorson C, Pearson J, Burger L, et al. An Sp1-binding site and TATA element are sufficient to support full transactivation by proximally bound NS1 protein of minute virus of mice. Virology 1998; 240: 326-337.
15. Fioretti F, Fradelizi D, Stoppacciaro A, et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 1998; 161: 342-346.
16. Rakhmilevich AL, Timmins JG, Janssen K, et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22: 135-144.
17. Kleine K, Konig G, Kreuzer J, et al. The effect of the JE (MCP-1) gene, which encodes monocyte chemoattrachtant protein-1, on the growth of HeLa cells and derived somatic-cell hybrids in nude mice. Mol Carcinog 1995; 14: 179-189.
18. Zhang JF, Hu C, Geng Y, et al. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther 1996; 3: 31-38.
19. Haddada H, Ragot T, Cordier L, et al. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-711.
20. Schmiegel W, Schmielau J, Henne-Bruns D, et al. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci U S A 1997; 94: 12622-12626.
21. Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999; 6: 808-815.
22. Wuyts A, Struyf S, Proost P, et al. Chemokines. In The Cytokine Network and Immune Functions, Thèze J (ed.). Oxford University Press: Oxford, UK, 1999; 125-145.
23. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705.
24. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
25. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999; 20: 254-257.
26. Kennedy J, Keiner GS, Kleyensteuber S, et al. Molecular cloning and functional characterization of human lymphotactin. J Immunol 1995; 155: 203-209.
27. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
28. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol 1996; 59: 67-74.
29. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999; 10: 61-86.
30. Van Damme J, Proost P, Put W, et al. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA. J Immunol 1994; 152: 5495-5502.
31. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-162.
32. Hirose K, Hakozaki M, Nyunoya Y, et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 1995; 72: 708-714.
33. Bottazzi B, Walter S, Govoni D, et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-1285.
34. Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996; 7: 1545-1553.
35. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-1095.
36. Huang S, Xie K, Singh RK, et al. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytokine Res 1995; 15: 655-665.
37. Huang S, Singh RK, Xie K, et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 1994; 39: 231-238.
38. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991; 11: 3125-3131.
39. Mantovani A, Vecchi A, Sozzani S, et al. Tumors as a paradigm for the in vivo role of chemokines in leukocyte recruitment. In Chemokines and Cancer, Rollins BJ (ed.). Humana Press: Totowa, NJ, 1999; 35-49.
40. Van Damme J, Proost P, Lenaerts JP, et al. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992; 176: 59-65.
41. Opdenakker G, Froyen G, Fiten P, et al. Human monocyte chemotactic protein-3 (MCP-3): molecular cloning of the cDNA and comparison with other chemokines. Biochem Biophys Res Commun 1993; 191: 535-542.
42. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995; 95: 1370-1376.
43. Alam R, Forsythe P, Stafford S, et al. Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils. J Immunol 1994; 153: 3155-3159.
44. Allavena P, Bianchi G, Zhou D, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994; 24: 3233-3236.
45. Noso N, Proost P, Van Damme J, et al. Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. Biochem Biophys Res Commun 1994; 200: 1470-1476.
46. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994; 15: 127-133.
47. Sozzani S, Luini W, Borsatti A, et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 1997; 159: 1993-2000.
48. Bonecchi R, Polentarutti N, Luini W, et al. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol 1999; 162: 474-479.
49. Dieu-Nosjean MC, Vicari A, Lebecque S, et al. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 1999; 66: 252-262.
50. Zolotukhin S, Potter M, Hauswirth WW, et al. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Viroi 1996; 70: 4646-4654.
51. Menten P, Proost P, Struyf S, et al. Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and interferon-gamma reveals MCP-3 heterogeneity. Eur J Immunol 1999; 29: 678-685.
52. Moffatt S, Yaegashi N, Tada K, et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72: 3018-3028.
53. Deleu L, Fuks F, Spitkovsky D, et al. Opposite transcriptional effects of cyclic AMP-responsive elements in confluent or p27KIP-overexpressing cells versus serum-starved or growing cells. Mol Cell Biol 1998; 18: 409-419.
54. Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol 1983; 111: 112-124.
55. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-155.
56. Blink EJ, Trapani JA, Jans DA. Perforin-dependent nuclear targeting of granzymes: a central role in the nuclear events of granule-exocytosis-mediated apoptosis? Immunol Cell Biol 1999; 77: 206-215.
57. Ben-Baruch A, Xu L, Young PR, et al. Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3. J Biol Chem 1995; 270: 22123-22128.
58. Xu LL, McVicar DW, Ben-Baruch A, et al. Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils. Eur J Immunol 1995; 25: 2612-2617.
59. Combadiere C, Ahuja SK, Van Damme J, et al. Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. J Biol Chem 1995; 270: 29671-29675.
60. Sozzani S, Allavena P, Vecchi A, et al. The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol 1999; 66: 1-9.
61. Vecchi A, Massimiliano L, Ramponi S, et al. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol 1999; 66: 489-494.
62. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature 1998; 392: 86-89.